HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs (5’-TTN and 5’-CCD, where D is not C) compared to the previously engineered variant Un1Cas12f1 (Un1Cas12f1_ge4.1).
Enhanced CRISPR-Cas12f Variants
The enhancements made by HuidaGene to the CRISPR-Cas12f system are notable for their potential to revolutionize genome editing. The company’s work has led to the development of inducible-activated DD enOsCas12f1, an epigenetic editor known as miniCRISPRoff, and a gene expression activator (denOsCas12f1-VPR). These tools expand the capabilities of the CRISPR-Cas12f system, offering more precise and versatile editing options for researchers and scientists.
Details and Applications
More details on HuidaGene’s advancements in the CRISPR-Cas12f system can be found on their official channels. The company’s work is expected to have a significant impact on the biotechnology and medical fields, as these enhanced variants offer broader applications in gene editing and could lead to breakthroughs in treating genetic diseases and improving crop genetics.-Fineline Info & Tech
